GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Achieve Life Sciences Inc (STU:SP4P) » Definitions » ROE % Adjusted to Book Value

Achieve Life Sciences (STU:SP4P) ROE % Adjusted to Book Value : -35.36% (As of Mar. 2024)


View and export this data going back to 2014. Start your Free Trial

What is Achieve Life Sciences ROE % Adjusted to Book Value?

Achieve Life Sciences's ROE % for the quarter that ended in Mar. 2024 was -108.20%. Achieve Life Sciences's PB Ratio for the quarter that ended in Mar. 2024 was 3.06. Achieve Life Sciences's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2024 was -35.36%.


Achieve Life Sciences ROE % Adjusted to Book Value Historical Data

The historical data trend for Achieve Life Sciences's ROE % Adjusted to Book Value can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Achieve Life Sciences ROE % Adjusted to Book Value Chart

Achieve Life Sciences Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE % Adjusted to Book Value
Get a 7-Day Free Trial Premium Member Only Premium Member Only -108.81 -41.31 -43.00 -46.37 -

Achieve Life Sciences Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
ROE % Adjusted to Book Value Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3.07 -61.46 -19.01 - -35.36

Competitive Comparison of Achieve Life Sciences's ROE % Adjusted to Book Value

For the Biotechnology subindustry, Achieve Life Sciences's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Achieve Life Sciences's ROE % Adjusted to Book Value Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Achieve Life Sciences's ROE % Adjusted to Book Value distribution charts can be found below:

* The bar in red indicates where Achieve Life Sciences's ROE % Adjusted to Book Value falls into.



Achieve Life Sciences ROE % Adjusted to Book Value Calculation

Achieve Life Sciences's ROE % Adjusted to Book Value for the fiscal year that ended in Dec. 2023 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-839.94% / N/A
=N/A

Achieve Life Sciences's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2024 is calculated as

ROE % Adjusted to Book Value=ROE % / PB Ratio
=-108.20% / 3.06
=-35.36%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Achieve Life Sciences ROE % Adjusted to Book Value Related Terms

Thank you for viewing the detailed overview of Achieve Life Sciences's ROE % Adjusted to Book Value provided by GuruFocus.com. Please click on the following links to see related term pages.


Achieve Life Sciences (STU:SP4P) Business Description

Traded in Other Exchanges
Address
22722 29th Dr. SE, Suite 1000, Bothell, WA, USA, 98021
Achieve Life Sciences Inc is a specialty pharmaceutical company committed to advancing cytisinicline as a widely available treatment option to help people battling nicotine addiction. It is an established smoking cessation treatment that has been approved and marketed in Central and Eastern Europe. Achieve's focus is to address the global smoking health epidemic through the development and commercialization of cytisinicline. It has one operating segment, dedicated to the development and commercialization of cytisinicline for nicotine addiction.

Achieve Life Sciences (STU:SP4P) Headlines

No Headlines